Deep Dive Into ANI Prescription drugs Inventory: Analyst Views (6 Rankings) – ANI Prescription drugs (NASDAQ:ANIP)

Over the past three months, 6 analysts shared their evaluations of ANI Prescription drugs ANIP, revealing numerous outlooks from bullish to bearish.

The desk under offers a snapshot of their current rankings, showcasing how sentiments have advanced over the previous 30 days and evaluating them to the previous months.

The 12-month worth targets assessed by analysts reveal additional insights, that includes a median goal of $87.5, a excessive estimate of $94.00, and a low estimate of $80.00. This present common has decreased by 2.23% from the earlier common worth goal of $89.50.

Decoding Analyst Rankings: A Detailed Look

The evaluation of current analyst actions sheds mild on the notion of ANI Prescription drugs by monetary specialists. The next abstract presents key analysts, their current evaluations, and changes to rankings and worth targets.

| Analyst | Analyst Agency | Motion Taken | Score |Present Value Goal| Prior Value Goal |
|——————–|——————–|—————|—————|——————–|——————–|
|Vamil Divan |Guggenheim |Maintains |Purchase | $86.00|$86.00 |
|Oren Livnat |HC Wainwright & Co. |Maintains |Purchase | $94.00|$94.00 |
|Glen Santangelo |Jefferies |Declares |Purchase | $80.00|- |
|Ekaterina Knyazkova |JP Morgan |Declares |Chubby | $85.00|- |
|Vamil Divan |Guggenheim |Raises |Purchase | $86.00|$84.00 |
|Oren Livnat |HC Wainwright & Co. |Maintains |Purchase | $94.00|$94.00 |

Key Insights:

• Motion Taken: Analysts adapt their suggestions to altering market situations and firm efficiency. Whether or not they ‘Preserve’, ‘Increase’ or ‘Decrease’ their stance, it displays their response to current developments associated to ANI Prescription drugs. This data offers a snapshot of how analysts understand the present state of the corporate.
• Score: Analyzing developments, analysts provide qualitative evaluations, starting from ‘Outperform’ to ‘Underperform’. These rankings convey expectations for the relative efficiency of ANI Prescription drugs in comparison with the broader market.
• Value Targets: Analysts predict actions in worth targets, providing estimates for ANI Prescription drugs’s future worth. Inspecting the present and prior targets affords insights into analysts’ evolving expectations.

Navigating by means of these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of ANI Prescription drugs’s market standing. Keep knowledgeable and make data-driven selections with our Rankings Desk.

Keep updated on ANI Prescription drugs analyst rankings.

If you’re all in favour of following small-cap inventory information and efficiency you can begin by monitoring it right here.

Discovering ANI Prescription drugs: A Nearer Look

ANI Prescription drugs Inc develops, manufactures, and markets generic prescription prescribed drugs. It manufactures liquid, powder, and oral solid-dose merchandise. Its areas of product growth embrace narcotics, oncolytics, hormones and steroids, and sophisticated formulations involving extended-release and mixture merchandise. A few of its generic merchandise embrace Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The corporate operates in two segments which embrace Uncommon Illnesses and Manufacturers, Generics, and Others. Its geographical segments are the USA and Canada, of which the vast majority of its income comes from the USA.

ANI Prescription drugs’s Financial Affect: An Evaluation

Market Capitalization: With restricted market capitalization, the corporate is positioned under business averages. This displays a smaller scale relative to friends.

Income Progress: ANI Prescription drugs’s outstanding efficiency in 3M is obvious. As of 31 December, 2024, the corporate achieved a powerful income development charge of 44.75%. This signifies a considerable improve within the firm’s top-line earnings. As in comparison with its friends, the income development lags behind its business friends. The corporate achieved a development charge decrease than the typical amongst friends in Well being Care sector.

Web Margin: ANI Prescription drugs’s web margin is spectacular, surpassing business averages. With a web margin of -5.61%, the corporate demonstrates sturdy profitability and efficient value administration.

Return on Fairness (ROE): The corporate’s ROE is a standout performer, exceeding business averages. With a powerful ROE of -2.64%, the corporate showcases efficient utilization of fairness capital.

Return on Property (ROA): The corporate’s ROA is a standout performer, exceeding business averages. With a powerful ROA of -0.83%, the corporate showcases efficient utilization of property.

Debt Administration: With a below-average debt-to-equity ratio of 1.55, ANI Prescription drugs adopts a prudent monetary technique, indicating a balanced method to debt administration.

The Core of Analyst Rankings: What Each Investor Ought to Know

Benzinga tracks 150 analyst companies and experiences on their inventory expectations. Analysts usually arrive at their conclusions by predicting how a lot cash an organization will make sooner or later, often the upcoming 5 years, and the way dangerous or predictable that firm’s income streams are.

Analysts attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish their rankings on shares. Analysts usually charge every inventory as soon as per quarter or at any time when the corporate has a significant replace.

Analysts could complement their rankings with predictions for metrics like development estimates, earnings, and income, providing buyers a extra complete outlook. Nonetheless, buyers must be aware that analysts, like every human, can have subjective views influencing their forecasts.

Which Shares Are Analysts Recommending Now?

Benzinga Edge offers you prompt entry to all main analyst upgrades, downgrades, and worth targets. Type by accuracy, upside potential, and extra. Click on right here to remain forward of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.